Announcing New Clinical Trials
Additional clinical trials! (Note that our Clinical Trials page lists all active trials).
Clinical Research Trial with Eltrombopag – Now Open for Accrual Thrombocytopenia in patients with Myelodysplastic Syndromes
We would like to announce a phase I/II study (PMA112509) of eltrombopag in thrombocytopenic subjects with advanced Myelodysplastic Syndromes (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS), or de novo AML.
For further information regarding key eligibility criteria, please contact the MDS Foundation at 1-800-MDS-0839 or email ahassan@www.mds-foundation.org.
Click here to view study locations.
MDS Foundation International Meeting to Evaluate New Treatment Options and New Studies of the Genetics Underlying this Group of Malignant Blood Disorders
- New Treatments to be Discussed Include Potential of Drug Combinations
- Updates on assessing prognosis and deciding on treatment options to be presented
- Genetic Studies Help Unravel Complexities of Myelodysplastic Syndromes (MDS)
- Patient Seminar in Edinburgh May 20th
The Myelodysplastic Syndromes (MDS) Foundation today said significant advances in understanding and treating MDS will be discussed and evaluated at the 11th International Symposium on Myelodysplastic Syndromes (or MDS 2011). Researchers will present new information on different combination drug regimens, that aim to improve the results of hypomethylating agents, and other agents that effect the underlying abnormalities present in this disease. They will also discuss new findings regarding …
Click here to read the full press release
The MDS Foundation Says Regulatory Decision Approving VIDAZA® in the UK Provides an Essential Treatment Option to Patients
- VIDAZA is the only licensed drug shown in clinical trials to improve survival
The Myelodysplastic Syndromes (MDS) Foundation-an international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes-today issued a statement applauding a decision from the National Institute for Health and Clinical Excellence in the UK (NICE) to recommend VIDAZA (azacitidine) in its approved indications for certain MDS patients.
Click here for more information
MDS Patients Achieve Access to Vital New Treatment Option
- National Institute for Health and Clinical Excellence recommend azacitidine is available through the NHS
London, 17 February 2011 – The National Institute for Health and Clinical Excellence (NICE) announced today that Vidaza (azacitidine), the only licensed drug available specifically to treat myelodysplastic syndromes (MDS) – a range of life-threatening bone
marrow disorders – will be available through the NHS. The MDS UK Patient Support Group, which has been in consultation with NICE during the approval process and campaigned on behalf and in conjunction with MDS patients across the UK, welcomes this announcement.
Click here to read the full press release
Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO)
Currently Recruiting Participants. The primary purpose of this study is to prospectively assess the efficacy and safety of iron chelation therapy with deferasirox compared to placebo in patients with myelodysplastic syndromes (low/int-1 risk) and transfusional iron overload. Contact the Novartis Clinical Trials Hotline at 800-340-6843 or click here for additional information and to view the active sites.
